Stocks of Precigen Inc (NASDAQ:PGEN) traded higher last session on Wall Street, up 13.47% to $1.01.
According to the data, Precigen Inc (NASDAQ:PGEN) has 5 analysts covering its stock. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $14.00 and a low of $6.00, we find $9.00. Given the previous closing price of $0.89, this indicates a potential upside of 911.24 percent. PGEN stock price is now -21.23% away from the 50-day moving average and -21.03% away from the 200-day moving average. The market capitalization of the company currently stands at $251.41M.
A total of 1 analysts have issued a hold rating and 4 have given it a buy rating. Brokers who have rated the stock have averaged $9.50 as their price target over the next twelve months.
In other news, MITCHELL DEAN J, Director bought 25,000 shares of the company’s stock on Sep 22. The stock was bought for $35,250 at an average price of $1.41. Upon completion of the transaction, the Director now directly owns 356,836 shares in the company, valued at $0.36 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 25, President and CEO Sabzevari Helen sold 76,969 shares of the business’s stock. A total of $117,763 was realized by selling the stock at an average price of $1.53. This leaves the insider owning 1,560,004 shares of the company worth $1.58 million. Insiders disposed of 359,020 shares of company stock worth roughly $0.36 million over the past 1 year. A total of 48.49% of the company’s stock is owned by insiders.
Tuesday’s opening bell rang with an opening price of $0.9003 for Precigen Inc (NASDAQ: PGEN). During the past 12 months, Precigen Inc has had a low of $0.81 and a high of $2.29. As of last week, the company has a debt-to-equity ratio of 0.05, a current ratio of 2.83, and a quick ratio of 2.83. The fifty day moving average price for PGEN is $1.2826 and a two-hundred day moving average price translates $1.2792 for the stock.
The latest earnings results from Precigen Inc (NASDAQ: PGEN) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$0.08, inline with analysts’ expectations of -$0.08. This compares to $0.48 EPS in the same period last year. The net profit margin was -1257.75% and return on equity was -58.59% for PGEN. The company reported revenue of $1.38 million for the quarter, compared to $16.72 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -91.75 percent. For the current quarter, analysts expect PGEN to generate $1.68M in revenue.
Precigen Inc(PGEN) Company Profile
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. The company operates through two segments, Biopharmaceuticals and Exemplar. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and Lactococcus lactis, a food-grade bacterium. Additionally, it provides RheoSwitch Therapeutic System, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
